The role of bureaucracy in evaluating diagnostic and therapeutic outcomes in an oncology service

Evaluating an oncology service requires considering multiple factors, because the diagnostic process and the determination of subsequent management involve various medical specialties, the Health Insurance Fund and pharmaceutical suppliers.

For instance, delays can occur in scheduling imaging tests – a situation that has improved recently in major cities, albeit with some exceptions.

Subsequent delays arise in performing immunohistochemical examinations and genetic testing, hindering timely therapeutic decision-making.

Sometimes, if the disease progresses rapidly or at the patient’s request, conventional cytotoxic treatment is initiated; while the regimen may be modified once genetic test results arrive, the – let us say – official protocol can no longer be strictly followed.

Another cause for treatment delays is that, even when all necessary data are available, the funds required to procure the medication may be lacking. In such cases, a request for additional funding is submitted to the Health Insurance Fund. Once these funds are received, the medication is ordered, and there is a further wait for suppliers to deliver the products.

All these delays can lead to disease progression, and it has been demonstrated that a late start to treatment results in reduced survival rates.

In the article “The Hidden Harm of Administrative Toxicity”, authors Frantz M. Berthaud (FACHE) and Christabel K. Cheung evaluate the following aspects of bureaucracy: “Clinical toxicity is expected and financial toxicity is now widely recognized. However, administrative toxicity – and its related construct, logistic toxicity – remains underdefined, undertheorized, and insufficiently measured. Although commonly framed as a clinician or system inconvenience, administrative toxicity is a direct, material harm experienced by patients. Delays in care, misaligned incentives, duplicative documentation requirements, opaque payer processes, and fragmented coordination can convert bureaucratic friction into clinical consequences. In oncology – where even short delays may shift prognosis – burdens represent not only inefficiencies but system-generated hazards that endanger timely access to evidence-based care”.